Halozyme Therapeutics (HALO) Stock Analysis

November 11, 2026

This is a peer-relative look at Halozyme Therapeutics (HALO): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Company profile fields for Halozyme Therapeutics (HALO)
Profile Item	HALO
Name	Halozyme Therapeutics Inc.
Country/Region	United States
GICS Sector	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology
GICS Sub-Industry	Biotechnology
Market Capitalization	11.81 billion USD
Currency	USD
Exchange	Nasdaq
Listing Date	March 16, 2004
Security Type	Common Stock

Price Performance

Cumulative Growth

HALO

GSPC

Halozyme Therapeutics (HALO) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Halozyme Therapeutics (HALO) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Halozyme Therapeutics (HALO) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Halozyme Therapeutics (HALO) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: HALO	Industry group median
Total Return (1Y)	50.94%	24.62%
Total Return (3Y, Annualized)	41.08%	20.37%
Total Return (5Y, Annualized)	21.68%	-4.02%

Risk Profile

Drawdown History

HALO

GSPC

Halozyme Therapeutics (HALO) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Halozyme Therapeutics (HALO) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Halozyme Therapeutics (HALO) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: HALO	Industry group median
Volatility (1Y, Annualized)	41.19%	66.36%
Beta (5Y)	0.96	0.93
Max Drawdown (5Y)	-49.06%	-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. HALO is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

Halozyme Therapeutics (HALO) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: HALO	Industry group median
Sharpe Ratio (1Y)	1.13	0.36
Sortino Ratio (1Y)	1.78	0.58

Profitability

ROE (TTM)

Halozyme Therapeutics (HALO) posts ROE of 216.38%, above the industry benchmark range. Equity is being turned into profit at an exceptional rate, but very high ROE should still be checked against leverage, buybacks, and the size of the equity base.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

216.38%

Group distribution

HALO: 216.38%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Largest peers

HALO: 216.38%
LLY: 86.02%
NVS: 24.33%
AZN: 22.57%
JNJ: 20.02%
MRK: 5.06%
ABBV: --

Where Halozyme Therapeutics (HALO) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

Halozyme Therapeutics (HALO) keeps 26.93% of revenue as net profit on net margin, above the industry benchmark range. That is unusually strong bottom-line conversion, though tax effects, asset sales, or other one-off gains should be checked before treating it as durable.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.93%

Group distribution

HALO: 26.93%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Largest peers

LLY: 31.90%
HALO: 26.93%
AZN: 17.68%
NVS: 17.49%
JNJ: 16.20%
ABBV: 15.67%
MRK: 3.64%

Where Halozyme Therapeutics (HALO) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

Halozyme Therapeutics (HALO) turns 59.84% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

59.84%

Group distribution

Max: 83.12%
HALO: 59.84%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Largest peers

HALO: 59.84%
LLY: 53.66%
ABBV: 39.59%
MRK: 35.22%
NVS: 34.27%
AZN: 29.57%
JNJ: 25.74%

Where Halozyme Therapeutics (HALO) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

Halozyme Therapeutics (HALO) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: HALO	Industry group median
ROE (TTM)	216.38%	-26.66%
ROA (TTM)	22.42%	-12.50%
Net Margin (TTM)	26.93%	0.00%
Operating Margin (TTM)	59.84%	0.00%
Gross Margin (TTM)	77.74%	37.87%

Growth

Revenue Growth

Halozyme Therapeutics (HALO) grew revenue 37.55%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

Halozyme Therapeutics (HALO): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

Halozyme Therapeutics (HALO) grew earnings per share -25.36%, roughly around the peer group's normal range. Bottom-line momentum looks broadly typical for the industry.

Halozyme Therapeutics (HALO): EPS Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

Growth Metrics

Halozyme Therapeutics (HALO) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: HALO	Industry group median
Revenue Growth (YoY)	37.55%	11.45%
Revenue Growth (3Y CAGR)	28.38%	9.94%
EPS Growth (YoY)	-25.36%	4.28%
EPS Growth (3Y CAGR)	21.14%	4.17%

Financial Strength

Current Ratio (MRQ)

Halozyme Therapeutics (HALO) has current ratio of 3.88, in the healthier middle range for its industry. The short-term asset cushion looks balanced relative to peers rather than stretched thin.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.88

Group distribution

Max: 25.13
Q3: 12.13
Median: 5.52
HALO: 3.88
Q1: 2.47
Min: 0.10

Largest peers

HALO: 3.88
LLY: 1.39
MRK: 1.35
JNJ: 1.02
AZN: 1.01
NVS: 0.88
ABBV: 0.87

Where Halozyme Therapeutics (HALO) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

No usable debt-to-equity ratio is available for Halozyme Therapeutics (HALO) this period, so the balance-sheet leverage read is skipped.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

Group distribution

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
HALO: --

Largest peers

NVS: 1.29
LLY: 1.23
MRK: 1.20
AZN: 0.66
JNJ: 0.55
HALO: --
ABBV: --

Halozyme Therapeutics (HALO) doesn’t report debt-to-equity ratio this period; the box shows the Pharmaceuticals, Biotechnology & Life Sciences group’s distribution and the dots its largest members.

Financial Strength Metrics

Halozyme Therapeutics (HALO) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: HALO	Industry group median
Current Ratio (MRQ)	3.88	5.52
Debt / Equity (MRQ)	--	0.15
Net Debt / EBITDA	1.90	1.08

Dividends

Dividend Yield (TTM)

Halozyme Therapeutics (HALO) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

HALO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

NVS: 2.88%
ABBV: 2.40%
MRK: 2.29%
JNJ: 1.94%
AZN: 1.73%
LLY: 0.49%
HALO: 0.00%

Where Halozyme Therapeutics (HALO) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

Halozyme Therapeutics (HALO) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

HALO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

MRK: 343.43%
ABBV: 117.35%
NVS: 90.46%
JNJ: 80.12%
AZN: 45.38%
LLY: 21.71%
HALO: 0.00%

Where Halozyme Therapeutics (HALO) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

Halozyme Therapeutics (HALO) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: HALO	Industry group median
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Halozyme Therapeutics (HALO) trades at P/E ratio of 25.91, near the industry’s usual earnings multiple. The stock is not showing a clear peer discount or premium on trailing earnings.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.91

Group distribution

Max: 85.34
Q3: 43.46
Median: 26.69
HALO: 25.91
Q1: 13.30
Min: 0.07

Largest peers

MRK: 148.21
ABBV: 50.05
LLY: 43.95
JNJ: 41.92
NVS: 31.02
AZN: 26.37
HALO: 25.91

Where Halozyme Therapeutics (HALO) stands on P/E ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/S Ratio (TTM)

Halozyme Therapeutics (HALO) trades at 6.55 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.55

Group distribution

Max: 58.18
Q3: 25.77
Median: 7.30
HALO: 6.55
Q1: 3.01
Min: 0.01

Largest peers

LLY: 13.95
ABBV: 7.80
JNJ: 6.69
HALO: 6.55
MRK: 5.37
NVS: 5.35
AZN: 4.63

Where Halozyme Therapeutics (HALO) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

Halozyme Therapeutics (HALO) has negative P/B ratio of -213.67, which means reported book equity is negative. Price-to-book breaks down in this situation and should not be used as a valuation signal.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-213.67

Group distribution

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59
HALO: -213.67

Largest peers

LLY: 29.96
NVS: 8.25
JNJ: 8.16
MRK: 8.06
AZN: 5.59
ABBV: -112.34
HALO: -213.67

Where Halozyme Therapeutics (HALO) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

Halozyme Therapeutics (HALO) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: HALO	Industry group median
P/E Ratio (TTM)	25.91	26.69
P/S Ratio (TTM)	6.55	7.30
P/B Ratio (MRQ)	-213.67	3.25
Free Cash Flow Yield (TTM)	3.48%	-1.66%